Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the <font color="red">effects_1</font> <font color="red">on_1</font> <font color="red">airway_1</font> <font color="red">inflammation_1</font> in asthma . 
<br>
<br> BACKGROUND Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids , and little is known about the effects of different treatments on airway inflammation . In this double - blind , placebo - controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP / M ) on <font color="red">sputum_1</font> <font color="red">inflammatory_1</font> <font color="red">markers_1</font> <font color="red">,_1</font> <font color="red">airway_1</font> <font color="red">responsiveness_1</font> <font color="red">,_1</font> <font color="red">lung_1</font> <font color="red">function_1</font> <font color="red">,_1</font> and <font color="red">symptoms_1</font> in adult asthmatics . 
<br> METHODS Sixty - six subjects were randomised to SFC or FP / M for 12 weeks . The primary outcome was <font color="red">changes_1</font> <font color="red">in_1</font> <font color="red">neutrophil_1</font> <font color="red">,_1</font> <font color="red">eosinophil_1</font> <font color="red">,_1</font> <font color="red">macrophage_1</font> <font color="red">,_1</font> <font color="red">lymphocyte_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">epithelial_1</font> <font color="red">cell_1</font> <font color="red">levels_1</font> <font color="red">in_1</font> <font color="red">induced_1</font> <font color="red">sputum_1</font> <font color="red">._1</font> Additional outcomes included the <font color="red">change_1</font> <font color="red">in_1</font> <font color="red">other_1</font> <font color="red">sputum_1</font> <font color="red">markers_1</font> <font color="red">of_1</font> <font color="red">airway_1</font> <font color="red">inflammation_1</font> <font color="red">,_1</font> <font color="red">airway_1</font> <font color="red">responsiveness_1</font> <font color="red">,_1</font> <font color="red">symptom_1</font> <font color="red">control_1</font> <font color="red">,_1</font> and <font color="red">lung_1</font> <font color="red">function_1</font> <font color="red">._1</font> 
<br> RESULTS Both treatments had no significant effect on <font color="red">induced_1</font> <font color="red">sputum_1</font> <font color="red">inflammatory_1</font> <font color="red">cells_1</font> <font color="red">,_1</font> although there was a trend for a reduction in <font color="red">sputum_1</font> <font color="red">eosinophils_1</font> <font color="red">._1</font> Both treatments significantly improved <font color="red">airway_1</font> <font color="red">responsiveness_1</font> <font color="red">,_1</font> whereas SFC generally led to greater improvements in <font color="red">symptom_1</font> <font color="red">control_1</font> and <font color="red">lung_1</font> <font color="red">function_1</font> than FP / M. FP / M led to significantly greater reductions in <font color="red">sputum_1</font> <font color="red">cysteinyl_1</font> <font color="red">leukotrienes_1</font> than SFC ( treatment ratio 1.80 ; 95% CI 1.09 , 2.94 ) . 
<br> CONCLUSION Both treatments led to similar control of <font color="red">eosinophilic_1</font> <font color="red">airway_1</font> <font color="red">inflammation_1</font> <font color="red">,_1</font> although PEF and symptom control were better with SFC . STUDY NUMBER : SAM40030 ( SOLTA ) .